Published in Gene Therapy Weekly, November 24th, 2005
The European Union Framework Programme (FP6) will enable doctors to improve 'T-cell mediated immunotherapy', which has the potential to fight a broad range of cancers.
The 5-year 'ATTACK' Project (Adoptive engineered T-cell Targeting to Activate Cancer Killing), involves an international consortium of 16 partners, who will collaborate on the process of engineering T-cells.
T-cells are part of the body's immune defense machinery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.